Tags

Type your tag names separated by a space and hit enter

Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
J Chemother 2013; 25(1):41-8JC

Abstract

From 1997 to 2003, 40 patients (all <40 years of age) with non-metastatic osteosarcoma of the extremities were treated with OOS-D and definitive surgery. Two cycles of doxorubicin 90 mg/m(2) plus cisplatin 120 mg/m(2) and ifosfamide 15 g/m(2) were given as neoadjuvant chemotherapy, and two cycles of doxorubicin/cisplatin and ifosfamide, and two cycles of high-dose methotrexate (10-12 g/m(2)) were given post-operatively. All patients underwent limb salvage surgeries, and 66% showed good response to neoadjuvant chemotherapy. With a median follow-up period of 117 months, 31 of the evaluable 40 patients were continuously disease-free, 7 were currently alive with no evidence of disease, and 2 died of disease. There was no local recurrence. The 5-year event-free and overall survival rates were 83 and 98%, respectively. The 10-year event-free and overall survival rates were 80 and 95%, respectively. The major form of toxicity was haematological one.

Authors+Show Affiliations

Osaka National Hospital, Osaka, Japan. kudawara@onh.go.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Multicenter Study

Language

eng

PubMed ID

23433444

Citation

Kudawara, Ikuo, et al. "Neoadjuvant and Adjuvant Chemotherapy With High-dose Ifosfamide, Doxorubicin, Cisplatin and High-dose Methotrexate in Non-metastatic Osteosarcoma of the Extremities: a Phase II Trial in Japan." Journal of Chemotherapy (Florence, Italy), vol. 25, no. 1, 2013, pp. 41-8.
Kudawara I, Aoki Y, Ueda T, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25(1):41-8.
Kudawara, I., Aoki, Y., Ueda, T., Araki, N., Naka, N., Nakanishi, H., ... Yoshikawa, H. (2013). Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. Journal of Chemotherapy (Florence, Italy), 25(1), pp. 41-8. doi:10.1179/1973947812Y.0000000055.
Kudawara I, et al. Neoadjuvant and Adjuvant Chemotherapy With High-dose Ifosfamide, Doxorubicin, Cisplatin and High-dose Methotrexate in Non-metastatic Osteosarcoma of the Extremities: a Phase II Trial in Japan. J Chemother. 2013;25(1):41-8. PubMed PMID: 23433444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. AU - Kudawara,Ikuo, AU - Aoki,Yasuaki, AU - Ueda,Takafumi, AU - Araki,Nobuhito, AU - Naka,Norifumi, AU - Nakanishi,Hirofumi, AU - Matsumine,Akihiko, AU - Ieguchi,Makoto, AU - Mori,Shigeki, AU - Myoui,Akira, AU - Kuratsu,Shigeyuki, AU - Hashimoto,Nobuyuki, AU - Yoshikawa,Hideki, PY - 2013/2/26/entrez PY - 2013/2/26/pubmed PY - 2013/9/21/medline SP - 41 EP - 8 JF - Journal of chemotherapy (Florence, Italy) JO - J Chemother VL - 25 IS - 1 N2 - From 1997 to 2003, 40 patients (all <40 years of age) with non-metastatic osteosarcoma of the extremities were treated with OOS-D and definitive surgery. Two cycles of doxorubicin 90 mg/m(2) plus cisplatin 120 mg/m(2) and ifosfamide 15 g/m(2) were given as neoadjuvant chemotherapy, and two cycles of doxorubicin/cisplatin and ifosfamide, and two cycles of high-dose methotrexate (10-12 g/m(2)) were given post-operatively. All patients underwent limb salvage surgeries, and 66% showed good response to neoadjuvant chemotherapy. With a median follow-up period of 117 months, 31 of the evaluable 40 patients were continuously disease-free, 7 were currently alive with no evidence of disease, and 2 died of disease. There was no local recurrence. The 5-year event-free and overall survival rates were 83 and 98%, respectively. The 10-year event-free and overall survival rates were 80 and 95%, respectively. The major form of toxicity was haematological one. SN - 1973-9478 UR - https://www.unboundmedicine.com/medline/citation/23433444/Neoadjuvant_and_adjuvant_chemotherapy_with_high_dose_ifosfamide_doxorubicin_cisplatin_and_high_dose_methotrexate_in_non_metastatic_osteosarcoma_of_the_extremities:_a_phase_II_trial_in_Japan_ L2 - http://www.tandfonline.com/doi/full/10.1179/1973947812Y.0000000055 DB - PRIME DP - Unbound Medicine ER -